Cautious. 7575.TWO scores 32.5/100 on Growth Compounder metrics, indicating below-average earnings momentum and profitability relative to peers. Leadership Alignment at 45/100 suggests moderate misalignment between management incentives and shareholder interests—likely driven by dilutive equity practices or weak governance controls. Without sufficient growth or capital-allocation discipline, the risk-reward is unfavorable for new money.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Amed:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 41/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Amed (7575.TWO) at 41/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. 7575.TWO scores 32.5/100 on Growth Compounder metrics, indicating below-average earnings momentum and profitability relative to peers. Leadership Alignment at 45/100 suggests moderate misalignment between management incentives and
7575.TWO's current Stocky Verdict is 41/100, placing it in the "Cautious" band. This composite combines a 33/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Amed yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Amed scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for Amed covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on 7575.TWO — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for 7575.TWO in the app.
